Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Louise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis, Simon H Rasmussen, Ulf Lindström, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K Wallman, Bjorn Gudbjornsson, Thorvardur Jon Love, Dan C Nordström, Timo Yli-Kerttula, Lucie Nekvindová, Jiří Vencovský, Florenzo Iannone, Alberto Cauli, Anne Gitte Loft, Bente Glintborg, Karin Laas, Ziga Rotar, Matija Tomšič, Gary J Macfarlane, Burkhard Möller, Marleen van de Sande, Catalin Codreanu, Michael J Nissen, Merih Birlik, Sukran Erten, Maria J Santos, Elsa Vieira-Sousa, Merete L Hetland, Mikkel Østergaard
OBJECTIVES: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data...
June 14, 2023: Rheumatology
#2
JOURNAL ARTICLE
Jon Salmanton-García, Fiona A Stewart, Sarah Heringer, Markela Koniordou, Elena Álvarez-Barco, Christos D Argyropoulos, Sophia C Themistocleous, Paula Valle-Simón, Orly Spivak, Lenka Součková, Christina Merakou, Maria Amélia Mendonça, Ruth Joanna Davis, Anna Maria Azzini, Helena H Askling, Sirkka Vene, Pierre Van Damme, Angela Steinbach, George Shiamakkides, Danila Seidel, Ole F Olesen, Evgenia Noula, Alan Macken, Catarina Luís, Janina Leckler, Odile Launay, Catherine Isitt, Margot Hellemans, Jesús Frías-Iniesta, Romina Di Marzo, Antonio J Carcas, George Boustras, Alberto M Borobia, Imre Barta, Kerstin Albus, Murat Akova, Jordi Ochando, Miriam Cohen-Kandli, Rebecca Jane Cox, Petr Husa, Ligita Jancoriene, Patrick Mallon, Laura Marques, Sibylle C Mellinghoff, Pontus Nauclér, Evelina Tacconelli, Krisztina Tóth, Theoklis E Zaoutis, Markus Zeitlinger, Oliver A Cornely, Zoi-Dorothea Pana
INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry...
July 29, 2022: Vaccine
#3
JOURNAL ARTICLE
Saedis Saevarsdottir, Thorunn A Olafsdottir, Erna V Ivarsdottir, Gisli H Halldorsson, Kristbjorg Gunnarsdottir, Asgeir Sigurdsson, Ari Johannesson, Jon K Sigurdsson, Thorhildur Juliusdottir, Sigrun H Lund, Asgeir O Arnthorsson, Edda L Styrmisdottir, Julius Gudmundsson, Gerdur M Grondal, Kristjan Steinsson, Lars Alfredsson, Johan Askling, Rafn Benediktsson, Ragnar Bjarnason, Arni J Geirsson, Bjorn Gudbjornsson, Hallgrimur Gudjonsson, Haukur Hjaltason, Astradur B Hreidarsson, Lars Klareskog, Ingrid Kockum, Helga Kristjansdottir, Thorvardur J Love, Bjorn R Ludviksson, Tomas Olsson, Pall T Onundarson, Kjartan B Orvar, Leonid Padyukov, Bardur Sigurgeirsson, Vinicius Tragante, Kristbjorg Bjarnadottir, Thorunn Rafnar, Gisli Masson, Patrick Sulem, Daniel F Gudbjartsson, Pall Melsted, Gudmar Thorleifsson, Gudmundur L Norddahl, Unnur Thorsteinsdottir, Ingileif Jonsdottir, Kari Stefansson
Autoimmune thyroid disease is the most common autoimmune disease and is highly heritable1 . Here, by using a genome-wide association study of 30,234 cases and 725,172 controls from Iceland and the UK Biobank, we find 99 sequence variants at 93 loci, of which 84 variants are previously unreported2-7 . A low-frequency (1.36%) intronic variant in FLT3 (rs76428106-C) has the largest effect on risk of autoimmune thyroid disease (odds ratio (OR) = 1.46, P = 2.37 × 10-24 ). rs76428106-C is also associated with systemic lupus erythematosus (OR = 1...
August 2020: Nature
#4
COMPARATIVE STUDY
Ola Olén, Johan Askling, Michael C Sachs, Paolo Frumento, Martin Neovius, Karin E Smedby, Anders Ekbom, Petter Malmborg, Jonas F Ludvigsson
BACKGROUND & AIMS: Childhood-onset inflammatory bowel disease (IBD) is believed to be a more severe disease than adult-onset IBD, but there is little information on all-cause and cause-specific mortality in patients with childhood-onset IBD. We performed a population-based cohort study, with 50 years of follow-up, to estimate absolute and relative risks for overall and cause-specific mortality in patients with childhood-onset IBD, during childhood and adulthood. METHODS: We identified children with a diagnosis of IBD (younger than 18 years) in the Swedish nationwide health registers (1964-2014; n = 9442) and individuals from the general population matched for sex, age, calendar year, and place of residence (reference group; n = 93,180)...
February 2019: Gastroenterology
#5
JOURNAL ARTICLE
O Olén, J Askling, M C Sachs, P Frumento, M Neovius, K E Smedby, A Ekbom, P Malmborg, J F Ludvigsson
Objective To assess risk of cancer in patients with childhood onset inflammatory bowel disease in childhood and adulthood. Design Cohort study with matched general population reference individuals using multivariable Cox regression to estimate hazard ratios. Setting Swedish national patient register (both inpatient and non-primary outpatient care) 1964-2014. Participants Incident cases of childhood onset (<18 years) inflammatory bowel disease (n=9405: ulcerative colitis, n=4648; Crohn's disease, n=3768; unclassified, n=989) compared with 92 870 comparators from the general population matched for sex, age, birth year, and county...
September 20, 2017: BMJ: British Medical Journal
#6
JOURNAL ARTICLE
Louise K Mercer, Anne C Regierer, Xavier Mariette, William G Dixon, Eva Baecklund, Karin Hellgren, Lene Dreyer, Merete Lund Hetland, René Cordtz, Kimme Hyrich, Anja Strangfeld, Angela Zink, Helena Canhao, M Victoria Hernandez, Florence Tubach, Jacques-Eric Gottenberg, Jacques Morel, Jakub Zavada, Florenzo Iannone, Johan Askling, Joachim Listing
BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma...
December 2017: Annals of the Rheumatic Diseases
#7
JOURNAL ARTICLE
O Olén, J Askling, P Frumento, M C Sachs, M Neovius, J Eriksson, K E Smedby, A Ekbom, P Malmborg, J F Ludvigsson
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
#8
JOURNAL ARTICLE
Lianne Kearsley-Fleet, Jakub Závada, Merete Lund Hetland, Dan C Nordström, Kalle J Aaltonen, Joachim Listing, Angela Zink, Tamas Gati, Bernadette Rojkovich, Florenzo Iannone, Elisa Gremese, Piet L C M van Riel, Martinus A F J van de Laar, Elisabeth Lie, Tore K Kvien, Helena Canhão, João E Fonseca, Žiga Rotar, Estibaliz Loza, Loreto Carmona, Johan Askling, Kari Johansson, Axel Finckh, William G Dixon, Kimme L Hyrich
OBJECTIVE: Under the auspices of the European League Against Rheumatism (EULAR), a study group of investigators representing European biologic DMARD (bDMARD) registers was convened. The purpose of this initial assessment was to collect and compare a cross section of patient characteristics and collate information on the availability of potential confounders within these registers. METHODS: Baseline characteristics of patients starting their first bDMARD in an arbitrary year (2008) for the treatment of RA, including demographic and disease characteristics, bDMARD drug details and co-morbidities, were collected and compared across 14 European bDMARD registers...
June 2015: Rheumatology
#9
RANDOMIZED CONTROLLED TRIAL
Carl M Askling, Magnus Tengvar, Olga Tarassova, Alf Thorstensson
BACKGROUND: Hamstring strain is a common injury in sprinters and jumpers, and therefore time to return to sport and secondary prevention become of particular concern. OBJECTIVE: To compare the effectiveness of two rehabilitation protocols after acute hamstring injury in Swedish elite sprinters and jumpers by evaluating time needed to return to full participation in the training process. STUDY DESIGN: Prospective randomised comparison of two rehabilitation protocols...
April 2014: British Journal of Sports Medicine
#10
JOURNAL ARTICLE
Jing Cui, Eli A Stahl, Saedis Saevarsdottir, Corinne Miceli, Dorothee Diogo, Gosia Trynka, Towfique Raj, Maša Umiċeviċ Mirkov, Helena Canhao, Katsunori Ikari, Chikashi Terao, Yukinori Okada, Sara Wedrén, Johan Askling, Hisashi Yamanaka, Shigeki Momohara, Atsuo Taniguchi, Koichiro Ohmura, Fumihiko Matsuda, Tsuneyo Mimori, Namrata Gupta, Manik Kuchroo, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Marieke Herenius, Marieke E Doorenspleet, Paul-Peter Tak, J Bart A Crusius, Irene E van der Horst-Bruinsma, Gert Jan Wolbink, Piet L C M van Riel, Mart van de Laar, Henk-Jan Guchelaar, Nancy A Shadick, Cornelia F Allaart, Tom W J Huizinga, Rene E M Toes, Robert P Kimberly, S Louis Bridges, Lindsey A Criswell, Larry W Moreland, João Eurico Fonseca, Niek de Vries, Barbara E Stranger, Philip L De Jager, Soumya Raychaudhuri, Michael E Weinblatt, Peter K Gregersen, Xavier Mariette, Anne Barton, Leonid Padyukov, Marieke J H Coenen, Elizabeth W Karlson, Robert M Plenge
Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers to predict response or new drugs to target refractory cases. To understand the biological basis of response to anti-TNF therapy, we conducted a genome-wide association study (GWAS) meta-analysis of more than 2 million common variants in 2,706 RA patients from 13 different collections...
March 2013: PLoS Genetics
#11
RANDOMIZED CONTROLLED TRIAL
Carl M Askling, Magnus Tengvar, Alf Thorstensson
BACKGROUND: Hamstring injury is the single most common injury in European professional football and, therefore, time to return and secondary prevention are of particular concern. OBJECTIVE: To compare the effectiveness of two rehabilitation protocols after acute hamstring injury in Swedish elite football players by evaluating time needed to return to full participation in football team-training and availability for match selection. STUDY DESIGN: Prospective randomised comparison of two rehabilitation protocols...
October 2013: British Journal of Sports Medicine
#12
COMPARATIVE STUDY
P Gautret, J P Cramer, V Field, E Caumes, M Jensenius, E Gkrania-Klotsas, P J de Vries, M P Grobusch, R Lopez-Velez, F Castelli, P Schlagenhauf, H Hervius Askling, F von Sonnenburg, D G Lalloo, L Loutan, C Rapp, F Basto, F Santos O'Connor, L Weld, P Parola
To investigate trends in travel-associated morbidity with particular emphasis on emerging infections with the potential for introduction into Europe, diagnoses of 7,408 returning travellers presenting to 16 EuroTravNet sites in 2010 were compared with 2008 and 2009. A significant increase in reported Plasmodium falciparum malaria (n=361 (6% of all travel-related morbidity) vs. n=254 (4%) and 260 (5%); p<0.001), P. vivax malaria (n=51 (1%) vs. n=31 (0.5%) and 38 (1%); p=0.027) and dengue fever (n=299 (5%) vs...
2012: Euro Surveillance
#13
JOURNAL ARTICLE
M Neovius, A Sundström, Jf Simard, B Wettermark, T Cars, N Feltelius, J Askling, L Klareskog
OBJECTIVE: To measure small-area variations in sales per capita of tumour necrosis factor (TNF) inhibitors. METHODS: For 2000-2009, sales data on etanercept, infliximab, and adalimumab were retrieved from the Swedish National Corporation of Pharmacies, which keeps data on drugs dispensed in ambulatory care and hospitals. As points of reference, data were retrieved on all drugs, non-biologic treatments for chronic inflammatory disorders (sulfasalazine, methotrexate, azathioprine), and for a biologic used in a different therapeutic area (trastuzumab)...
January 2011: Scandinavian Journal of Rheumatology
#14
JOURNAL ARTICLE
C M Askling, J Nilsson, A Thorstensson
PURPOSE: The aim was to introduce and evaluate the reliability and validity of an active hamstring flexibility test as a complement to common clinical examination when determining safe return to sport after hamstring injury. METHODS: Eleven healthy subjects (28 years) were tested on repeated occasions, and 11 athletes (21 years) with MRI-verified acute hamstring strain were tested when common clinical examination revealed no signs of remaining injury, i.e. there was no differences between the legs in palpation pain, manual strength tests, and passive straight leg raise...
December 2010: Knee Surgery, Sports Traumatology, Arthroscopy
#15
JOURNAL ARTICLE
T A Simon, A L Smitten, J Franklin, J Askling, D Lacaille, F Wolfe, M C Hochberg, K Qi, S Suissa
OBJECTIVE: To provide context for the malignancy experience in the rheumatoid arthritis (RA) abatacept clinical development programme (CDP) by performing comparisons with similar RA patients and the general population. METHODS: Malignancy outcomes included total malignancy (excluding non-melanoma skin cancer (NMSC)), breast, colorectal, lung cancers and lymphoma. Comparisons were made between the observed incidence in patients within the abatacept CDP and RA patients on disease-modifying antirheumatic drugs (DMARD) identified from five data sources: the population-based British Columbia RA Cohort, the Norfolk Arthritis Register, the National Data Bank for Rheumatic Diseases, the Sweden Early RA Register and the General Practice Research Database...
December 2009: Annals of the Rheumatic Diseases
#16
JOURNAL ARTICLE
Kristina B Mercer, Sarah M Szlam, Erin Manning, Kim M Gernert, Walter W Walthall, Guy M Benian, Claire-Anne Gutekunst
Huntingtin-associated protein 1 (HAP1) is a binding partner for huntingtin, the protein responsible for Huntington's disease. In mammals, HAP1 is mostly found in brain where it is expressed in neurons. Although several functions have been proposed for HAP1, its role has not yet been clearly established. In this paper, we report on the identification of a HAP1 Caenorhabditis elegans homolog called T27A3.1. T27A3.1 shows conservation with rat and human HAP1, as well as with Milton, a Drosophila HAP1 homolog. To determine the cellular expression of T27A3...
January 2009: Journal of Molecular Neuroscience: MN
#17
JOURNAL ARTICLE
J Askling, E Baecklund, F Granath, P Geborek, M Fored, C Backlin, L Bertilsson, L Cöster, L T Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, R van Vollenhoven, L Klareskog, N Feltelius
BACKGROUND: Tumour necrosis factor (TNF) antagonists have proved effective as treatment against rheumatoid arthritis (RA), but the unresolved issue of whether the use of anti-TNF therapy increases the already elevated risk of lymphoma in RA remains a concern. METHODS: Using the Swedish Biologics Register (ARTIS), the Swedish Cancer Register, pre-existing RA cohorts and cross-linkage with other national health and census registers, a national RA cohort (n = 67,743) was assembled and patients who started anti-TNF therapy between 1998 and July 2006 (n = 6604) were identified...
May 2009: Annals of the Rheumatic Diseases
#18
REVIEW
J Askling, C M Fored, P Geborek, L T H Jacobsson, R van Vollenhoven, N Feltelius, S Lindblad, L Klareskog
Data from several different monitoring systems are examined. The potential for registers based on data obtained from clinical practice, and linkage of such data to national health and population registers, is discussed. The approach described is a possible prototype for long term surveillance systems needed for the safe introduction of new treatments.
June 2006: Annals of the Rheumatic Diseases
#19
JOURNAL ARTICLE
J Askling, C M Fored, E Baecklund, L Brandt, C Backlin, A Ekbom, C Sundström, L Bertilsson, L Cöster, P Geborek, L T Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, L Klareskog, N Feltelius
BACKGROUND: Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas, and maybe also of leukaemia and multiple myeloma. The effect of tumour necrosis factor (TNF) antagonists on lymphoma risk and characteristics is unclear. OBJECTIVE: To assess expected rates and relative risks of haematopoietic malignancies, especially those associated with TNF antagonists, in large population based cohorts of patients with RA. METHODS: A population based cohort study was performed of patients with RA (one prevalent cohort (n = 53,067), one incident cohort (n = 3703), and one TNF antagonist treated cohort 1999 through 2003 (n = 4160)), who were linked with the Swedish Cancer Register...
October 2005: Annals of the Rheumatic Diseases
#20
JOURNAL ARTICLE
J Askling, C M Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelius, L Cöster, P Geborek, L T Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, L Klareskog
BACKGROUND: Existing studies of solid cancers in rheumatoid arthritis (RA) reflect cancer morbidity up until the early 1990s in prevalent cohorts admitted to hospital during the 1980s. OBJECTIVE: To depict the cancer pattern of contemporary patients with RA, from updated risk data from prevalent and incident RA populations. To understand the risk of solid cancer after tumour necrosis factor (TNF) treatment by obtaining cancer data from cohorts treated in routine care rather than trials...
October 2005: Annals of the Rheumatic Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
